Navigation Links
Clinical trial will test new HIV/AIDS vaccine
Date:4/3/2008

BOSTON A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Womens Hospital (BWH). This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.

This study will involve 48 healthy volunteers who will receive either two or three immunizations and who will be followed to assess the safety and immunogenicity of the vaccine, explains Lindsey R. Baden, MD, Assistant Professor of Medicine at BWH and Harvard Medical School and Protocol Chair for the study.

The vaccine consists of a replication-incompetent, recombinant adenovirus serotype 26 (rAd26) vector encoding an HIV-1 envelope gene.

The rAd26 vaccine vector was selected for its particularly low seroprevalence in human populations and for its potent immunogenicity and protective efficacy in preclinical studies, explains Dan H. Barouch, MD, PhD, Associate Professor of Medicine at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School and Principal Investigator of the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program that developed the vaccine. This program is sponsored by the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Manufactured by the Dutch biotechnology company Crucell Holland BV, the rAd26 vaccine is the first HIV-1 vaccine candidate to emerge from the IPCAVD initiative, which brings together investigators from academia and industry in an effort to accelerate the development of promising HIV/AIDS vaccine candidates. The novel strategy used in developing this vaccine enables researchers to circumvent preexisting immunity to the adenovirus serotype 5, the virus responsible for the common cold, which has recently shown limitations as an HIV-1 vaccine vector.

The rAd26 vector does not regularly occur in the human population and huma
'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... SUNDAY, July 13, 2014 (HealthDay News) -- Eye tests ... stages of Alzheimer,s disease, two new studies suggest. ... used a certain eye test found a significant association ... the eye and levels of the plaques in the ... Alzheimer,s disease. This type of eye test could ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 ... may have bigger brains and sharper thinking skills than their ... connection between playing games such as puzzles, crosswords, cards and ... 60s. Researchers found that people who played those games ... memory and other mental functions. And, based on MRI scans, ...
(Date:7/14/2014)... Many people are unhappy with their ... to reduce a “double chin.” A new product ... to go under the knife. Jawflex is a double ... therefore tightening the skin in that area and reducing ... used for facial exercise, double chin elimination and sagging ...
(Date:7/14/2014)... July 14, 2014 Many diet plans often ... study by the School of Public Health at the University ... had a near-zero effect on weight loss. Now experts are ... with some form of portion control to trigger ... monitoring portions and controlling how much is consumed, simply by ...
(Date:7/14/2014)... Sometimes, thinking “inside the box” can ... its first product release, Joyboxx™ - The world’s only ... , Inventor and CEO, Deborah Semer began designing ... storage solution for their ‘toys’ after she realized no ... industry. , Semer met 30-year industry veteran Phyllis Heppenstall, ...
Breaking Medicine News(10 mins):Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3
... Win Patient Safety Protections, OAKLAND, Calif., ... University of California medical centers throughout the ... majority, the California Nurses Association,announced today. The ... as resolving long-standing issues of pension and ...
... serious trauma live, often with little visible damage, surgeons say ... of war in Iraq, there,s some relatively good medical ... are now surviving injuries that would have been fatal in ... The Journal of Craniofacial Surgery , the surgical and treatment ...
... Mich., March 24 Perrigo Company,(Nasdaq: PRGO ... CEO Joseph,C. Papa will present at the 12th ... March 25, at 2:05 p.m. (ET) at the,Grand ... Company is a leading global healthcare supplier that ...
... Fitness,Corporation (OTC Bulletin Board: HFIT) today announced that ... repurchase up to $2.5 million of the,company,s outstanding ... shares on the open market in amounts and ... with Securities and Exchange,Commission Rule 10b-18 and other ...
... urged to discuss risk factors with their doctors, ... long been known that,psoriasis, a chronic skin condition ... bleed, can have a significant negative impact on ... finding that,psoriasis, especially severe psoriasis, is linked with ...
... International,Corporation (Nasdaq: PRXL ) announced today it will ... Conference. James Winschel, Senior Vice,President and Chief Financial Officer ... a.m. ET on Thursday, March 27, 2008., A ... the,"Investor Relations Webcasts" section of PAREXEL,s web site at, ...
Cached Medicine News:Health News:UC RNs Overwhelmingly Approve New Contract 2Health News:UC RNs Overwhelmingly Approve New Contract 3Health News:Innovative Care Is Helping Iraq War's Injured Survive 2Health News:Innovative Care Is Helping Iraq War's Injured Survive 3Health News:Health Fitness Announces $2.5 Million Stock Repurchase Plan 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 3Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 4Health News:PAREXEL International to Present at Bank of America 2008 Smid Cap Conference 2
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... , July 11, 2014 Research ... "Global Hypodermic Needles Market 2014-2018" report to their ... A hypodermic needle is a hollow needle commonly ... body or or to extract fluids from it. A ... or to inject substances that cannot be ingested. Hypodermic ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... 23, 2012 Event details: ... p.m. Renaissance Palm Springs Hotel ... , CA Ameritox(SM), the nation,s leader in ... emerging trends and technologies in medication monitoring at the American Academy of Pain ...
... , Inc. (Nasdaq: NXTM ), a leading ... of the Chronic Disease Research Group (CDRG) study which ... for daily, or more frequent, home hemodialysis, experienced a ... higher 3-year survival compared with that of patients treated ...
Cached Medicine Technology:Ameritox Provides Educational Support to Clinicians to Help Reduce Opioid Misuse, Abuse and Diversion 2Ameritox Provides Educational Support to Clinicians to Help Reduce Opioid Misuse, Abuse and Diversion 3Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys 2Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys 3Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: